Bicillin LA

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bicillin LA

What is Bicillin LA? A Quick Overview

Property Description
Active ingredient Benzathine Penicillin G
Form Injectable Suspension (Long-Acting)
Pharmacological Class Natural Penicillin; beta-Lactam Antibiotic
Primary Purpose Treatment and prevention of susceptible bacterial infections
Origin Naturally derived from Penicillium fungi

Bicillin L-A is the brand name for an injectable medicine containing the active ingredient Benzathine Penicillin G. This medication is a prescription-only drug formulated as a sterile, prolonged-release suspension intended solely for deep intramuscular (IM) injection. The distinct L-A (Long-Acting) feature signifies that the drug is designed to release slowly over several weeks, providing sustained therapeutic levels in the body.


What Type of Drug is Bicillin LA? Its Origin and Composition

Bicillin L-A belongs to the natural penicillin class and is chemically categorized as a beta-lactam antibiotic. Its primary compound, Penicillin G, is derived from the Penicillium fungi, placing it among the earliest antimicrobial agents.

The unique form, Benzathine Penicillin G, is a salt combination that prevents the compound from dissolving quickly. This insolubility is essential, as it facilitates the slow absorption from the muscle tissue into the bloodstream, which is what gives the medication its extended duration of action.


What is the Main Therapeutic Purpose of Bicillin LA?

The primary purpose of Bicillin L-A is to fight infections caused by susceptible bacteria and, critically, in the prevention of recurrent rheumatic fever. It is used as an essential medicine for the prophylaxis of rheumatic heart disease.

This long-acting nature makes it particularly suitable for managing conditions where consistent antibiotic coverage is required over time, offering a reliable, prolonged antimicrobial defense against targeted bacterial threats.

What side effects are possible with Bicillin LA?

Possible Side Effects and Safety Information

The official safety profile for Benzathine Penicillin G primarily centers on the potential for serious immunological responses and a range of systemic adverse effects, as organized in regulatory documents. The medication is contraindicated in patients with a known, prior hypersensitivity reaction (such as anaphylaxis) to any penicillin or to procaine.


Documented Adverse Reaction Categories

Adverse reactions are classified by System-Organ Class (SOC) in official labeling. These classes include Immune System Disorders, which covers severe events like anaphylactic shock and Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. Other affected systems include Gastrointestinal Disorders (e.g., nausea, diarrhea, and Clostridioides difficile-associated diarrhea) and Nervous System Disorders.

Specific contextual risks are also documented. For example, a Jarisch-Herxheimer Reaction—a transient febrile systemic reaction—may occur within the first 24 hours of administration when treating syphilis. Additionally, neurotoxicity, potentially leading to seizures, is a documented risk, particularly when high systemic drug levels are reached, such as in patients with severe renal impairment. Official labeling also notes that, for older adults, potential diminished renal function should be taken into account when assessing safety.

Overdose and Emergency Response

Overdose and when to seek help

The official prescribing information for Bicillin L-A (Benzathine Penicillin G) documents specific manifestations and the required actions in the event of a suspected overdose. The regulatory profile is strictly defined by the potential for severe, documented Central Nervous System (CNS) toxicity and the corresponding mandatory requirement for urgent professional medical evaluation.

Manifestations and Actions Official Regulatory Statements
Documented Overdose Presentations Massive overdose is associated with signs of neuromuscular hyperexcitability and the occurrence of convulsions (seizures). The CNS is the primary system affected.
Severe Outcomes The documented severity classification includes potential consequences such as coma and irreversible cerebral damage.
Help-Seeking Mandate Suspected overdose requires individuals to seek immediate medical attention. The official response statement is to Contact a Poison Control Center immediately.
Management & Constraints Treatment is defined as strictly symptomatic and supportive. Hemodialysis may be used as a procedure to aid drug removal. The official labeling confirms that no specific antidote is known.

Individuals with impaired renal function are noted in regulatory documents to be at an increased risk of severe adverse reactions, including convulsions, following an overdose, as elimination of the drug may be compromised.

Therapeutic Uses of Bicillin LA

What Bicillin LA Treats: Main Uses and Benefits

Bicillin L-A (Benzathine Penicillin G) is used to provide sustained support for managing bacterial presence and associated consequences. The medication's long-acting characteristic is used for supporting the elimination of targeted organisms and may contribute to preventing disease recurrence. Bicillin L-A is indicated for use across three primary therapeutic areas: managing syphilis and other treponemal infections like yaws and pinta; addressing mild-to-moderate streptococcal pharyngitis (Strep Throat); and providing secondary prophylaxis against rheumatic fever and chorea.

This long-acting formulation is often applied in situations requiring a context where sustained support is needed. “Sustained coverage is often applied to manage the risk of cumulative damage in recurrent conditions.” The therapeutic benefit is associated with supporting the elimination of the pathogen, which may assist with easing systemic symptoms and helping to maintain functional stability during difficult episodes.


Quick Fact: Support for Recurrent Disease Management Bicillin L-A is commonly used to support long-term prevention of rheumatic fever, which may help reduce the recurrence of symptoms and may assist with managing the risk of associated cardiovascular consequences.


Eligibility and Restrictions for Use

Who Can and Cannot Use Bicillin L-A?

The population eligibility for Bicillin L-A (Benzathine Penicillin G) is strictly defined by regulatory guidelines, focusing on absolute contraindications and conditions requiring caution.

Absolute Contraindications (Must Not Use)

Bicillin L-A is absolutely contraindicated for patients with a documented history of a previous hypersensitivity reaction to any of the penicillins. This restriction is mandatory for patient safety. Patients with hypersensitivity to lidocaine or procaine must also not use formulations containing these excipients.

Age-Related and Conditional Use

The medicine is generally approved for use in adults and pediatric patients for indicated infections. However, use is conditional in certain populations:

  • Impaired Renal Function: Caution is required because Bicillin L-A is largely excreted by the kidney, and impaired function can lead to delayed elimination and increased risk.
  • Older Adults (ge65 years): Dose selection must be cautious due to the higher potential for decreased kidney, liver, or heart function in this group.
  • Infants and Small Children: The injection site must be selected with extreme care to avoid the buttocks and major neurovascular structures.

Pregnancy and Lactation Eligibility

Bicillin L-A is classified as generally acceptable for use during pregnancy for appropriate indications, such as treating syphilis, where it is often the required therapy. Caution is advised during breastfeeding as the drug is known to be excreted into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Bicillin L-A (Benzathine Penicillin G) is defined by pharmacokinetic and pharmacodynamic patterns documented in regulatory sources.


Pharmacokinetic and Exposure Interactions

The most definitive pharmacokinetic interaction involves substances that interfere with the drug's renal excretion. Co-administration with Probenecid is known to inhibit the renal tubular secretion of penicillin G. This action prolongs the elimination of the antibiotic from the system, resulting in increased serum concentrations of penicillin G. There are no formal interactions documented as involving CYP-mediated enzyme inhibition or induction.


Pharmacodynamic and Other Interactions

Several pharmacodynamic interactions are noted in official labeling. Concurrent use with oral anticoagulants (e.g., Warfarin) may potentiate the risk of bleeding. Additionally, co-administration with bacteriostatic antibiotics, such as tetracyclines, may antagonize the bactericidal effect of penicillin G. Regulatory information also indicates a potential for reduced effectiveness when Bicillin L-A is combined with hormonal contraceptives.


Interaction-Related Considerations

No medicinal product combinations are explicitly classified as formally contraindicated. Regulatory documents note that the drug's effects may be increased in patients with impaired renal function due to the slower removal of penicillin G from the body. No mandatory timing-based separation rules or specific interactions with food, alcohol, or herbal products are documented in the prescribing information.

Mechanism of Action

How Bicillin L-A Works: Mechanism of Action

Bicillin L-A's mechanism targets the structural integrity of susceptible bacteria by focusing on a family of essential bacterial enzymes known as Penicillin-Binding Proteins (PBPs). The active component, Penicillin G, acts as an irreversible covalent inhibitor, permanently binding to and inactivating these PBPs. This inhibition specifically blocks the crucial peptidoglycan cross-linking process, which is the final step in constructing the bacterium's rigid outer cell wall. The resulting failure to build a structurally sound wall leads to rapid osmotic lysis—the physical rupture and death of the bacterial cell—which is the observed bactericidal physiological consequence.

The drug is formulated as a Benzathine salt, creating a depot effect at the injection site. This poorly soluble salt ensures the slow and continuous release of Penicillin G, which establishes the prolonged duration required to maintain PBP inhibition. However, the mechanism is constrained by bacterial countermeasures, such as the production of beta-lactamase enzymes that chemically degrade the drug's structure, preventing it from binding to the PBP targets.

Dosage and Administration Information

How Bicillin L-A is Used: Administration Guidelines

Bicillin L-A (Benzathine Penicillin G) is a prolonged-release suspension focused on a specific method and schedule of its delivery.

Administration Method and Route

The medication is formulated for administration only via deep intramuscular (IM) injection. This method is essential for facilitating the slow release of the active ingredient from the muscle tissue. Administration via intravenous (IV), intra-arterial (IA), or subcutaneous (SC) routes is prohibited. The correct injection site for adults is typically the upper, outer quadrant of the buttock, while for infants, the midlateral aspect of the thigh is often specified.

Standard Dosing and Frequency Patterns

Dosing is measured in units and varies by the indication. For many acute infections, such as mild-to-moderate streptococcal pharyngitis, the protocol is a single, one-time dose of 1,200,000 units for adults. Conversely, for conditions requiring sustained unit amounts over time, such as the treatment of late syphilis, the scheduled course involves 2,400,000 units given once weekly for a total of three doses.

Procedural and Population Requirements

The physical administration technique is critical: the viscous suspension must be injected at a slow, steady rate to prevent needle obstruction. Furthermore, large total volumes may require the dose to be divided between two separate injection sites. Dosing requires adjustment for specific populations; for example, infants and children receive a weight-based unit amount, and patients with renal impairment must have the unit amount reduced to align with renal clearance requirements.

Recent Clinical Evidence

Evidence for Syphilis and Other Treponemal Infections

Bicillin L-A was studied for treating various stages of syphilis and other treponemal infections like yaws, pinta, and bejel. The research in this area is supported by Randomized Controlled Trials (RCTs) and Systematic Reviews, which evaluate the use of the medicine. These studies primarily involved adults who had early-stage syphilis. Researchers monitored changes in specific blood test results (titer changes) over defined time intervals. Findings describe group patterns observed in these studies, helping to contextualize the outcomes measured in the observed populations. While evidence suggests outcomes related to serologic response in early syphilis, the evidence regarding long-term outcomes following treatment for late syphilis is often based on older, non-randomized study designs. Data for certain groups remain insufficient to draw broad conclusions across all potential regimens.


️ Evidence for Preventing Recurrent Rheumatic Fever

Bicillin L-A was studied for secondary prevention in individuals who have previously had Acute Rheumatic Fever (ARF) or have established Rheumatic Heart Disease (RHD). The evidence base here consists of Systematic Reviews and long-standing Observational/Cohort Studies. Decades of observational data described patterns in the frequency of ARF recurrence among individuals observed in these settings. Studies monitored adherence to the continuous injection schedule; data show patterns related to this factor, which researchers noted was a critical variable evaluated in the study. Limited research exists that specifically reports on the direct impact on RHD progression or measures of long-term outcomes using modern, large-scale RCTs. Therefore, long-term effects are not fully established.


Evidence for Treating Streptococcal Pharyngitis

Bicillin L-A was evaluated in research exploring the treatment of streptococcal pharyngitis (Strep Throat). This use was studied for the purpose of evaluating subsequent complications like Acute Rheumatic Fever. The evidence is derived from Randomized Trials and summarized in Systematic Reviews. Researchers examined outcomes related to the bacteriological eradication of the organism and monitored the subsequent incidence of ARF. Evidence quality varies across studies, and the certainty remains low for findings related to some outcomes. The primary research focus for this use remains the short-term evaluation of post-streptococcal sequelae.


Research Gaps and Areas of Uncertainty

While research provides context on how this treatment was observed in various populations, certain gaps and uncertainties remain. For instance, some of the historical evidence relies on older study designs, and the evidence quality varies across studies. A key limitation is the limited information for long-term outcomes regarding chronic disease progression. For example, research has not determined the extent to which continuous use ultimately influences the progression of heart damage (RHD). Follow-up durations were limited in studies monitoring the treatment of acute infections. Findings describe group patterns, and research highlights what is known, but evidence is limited regarding personalized outcomes.

Frequently Asked Questions (FAQ)

Common questions about Bicillin LA (FAQ)


Q: How quickly does Bicillin LA start working after the injection?

Bicillin L-A is designed as a prolonged-release suspension. Official product information explains that the active ingredient is slowly released from the muscle injection site into the bloodstream. Due to this slow absorption, the blood serum levels achieved are lower but more prolonged compared to other forms of penicillin, allowing the drug to work steadily over time.


Q: How long does the effect of a Bicillin LA injection last?

The long-acting nature of the medicine is designed to maintain detectable therapeutic levels in the body over time. According to official drug monographs, detectable blood concentrations may persist for 14 days following a 1,200,000 unit dose, and concentrations may still be detectable 4 weeks after a 2,400,000 unit dose.


Q: Does Bicillin LA interact with birth control pills?

Regulatory documents indicate a potential interaction with hormonal contraceptives, which includes certain types of birth control pills. Official information states that co-administration may result in a reduced effectiveness of the contraceptive medicine.


Q: Why does the injection site sometimes hurt or feel sore after getting Bicillin LA?

Official information, such as patient safety guides, documents that pain, swelling, a lump (induration), bleeding, or bruising in the area where the medicine was injected are documented side effects. This reaction is related to the required deep intramuscular injection of the suspension.


Q: What are the general expectations for a patient receiving Bicillin LA?

General guidance available in official sources advises that receiving all prescribed doses on schedule is necessary for appropriate treatment. Skipping doses or stopping treatment too soon is associated with the risk of incomplete treatment or the potential for bacterial resistance.


Q: Can Bicillin LA treat strep throat?

Yes, Bicillin L-A is indicated for the treatment of certain streptococcal infections (Group A, without bacteraemia). This includes mild-to-moderate infections of the upper respiratory tract, such as pharyngitis (commonly known as strep throat).


Q: Can children receive Bicillin LA?

Official information confirms that the medicine is approved for use in both adults and pediatric patients for its established indications. However, official guidelines indicate that special attention should be paid to the selection of the injection site when the drug is administered to infants and small children.


Q: Is Bicillin LA the same as Bicillin CR?

No, they are not the same. Official descriptions confirm that Bicillin L-A contains only benzathine penicillin G. Bicillin C-R is a mixture of benzathine penicillin G and procaine penicillin G, and they are chemically distinct formulations intended for specific uses.


Q: Can Bicillin LA be used for general viral infections like the flu?

No. Official labeling clearly states that antibacterial drugs like Bicillin L-A are effective only against bacterial infections. They do not treat viral infections such, as the common cold or the flu.


Q: Is Bicillin LA considered a strong antibiotic?

Bicillin L-A is classified as a natural penicillin and a beta-Lactam antibiotic. Its effectiveness is based on its bactericidal action—meaning it kills bacteria—against penicillin-susceptible microorganisms, such as Streptococcus pyogenes.


Q: Does Bicillin LA contain any sulfa ingredients?

No. According to the chemical description, the active ingredient in Bicillin L-A is Penicillin G benzathine. It is derived from the penicillin family and is not a sulfonamide (sulfa) antibiotic.


Q: What should I know about drug interactions when using Bicillin LA?

Regulatory documents list several known potential interactions. These include substances like Probenecid (which may increase drug levels), oral anticoagulants (may increase bleeding risk), and certain bacteriostatic antibiotics (may reduce effectiveness).


Q: Can Bicillin LA be taken if a person has kidney issues?

Official information indicates that use requires caution if a person has impaired renal (kidney) function. The drug is largely excreted by the kidney, and impaired function can lead to considerably delayed elimination and an increased potential risk of toxic reactions.


Q: Is Bicillin LA safe to use during pregnancy?

For appropriate indications, the classification is noted. For example, the Australian regulatory body (TGA) places Penicillin G Benzathine in Pregnancy Category A. This means the drug has been used by a large number of pregnant women without evidence of an increased frequency of birth defects.


Q: Are there any age restrictions for using Bicillin LA?

There are no absolute age restrictions. The medicine is approved for adults and pediatric patients. However, official information highlights that dose selection must be cautious for elderly patients (over 65 years) due to potential changes in organ function.


Q: What foods or supplements might interact with Bicillin LA?

According to the official prescribing information, there are no specific mandatory timing-based separation rules or documented interactions with food, alcohol, or herbal products that patients must follow.


Q: What kind of research supports the use of Bicillin LA for its main indications?

The efficacy of the drug is supported by historical and modern research, primarily based on bacteriological studies (including sensitivity tests) and clinical response data. These studies evaluate its effectiveness in treating infections caused by penicillin-sensitive microorganisms.


Q: Is it normal to feel tired after receiving Bicillin LA?

Fatigue (feeling tired) is noted as a documented symptom in official labeling that may potentially be associated with the drug. Official information also notes that symptoms like fatigue may occur as part of a Jarisch-Herxheimer reaction, which is a transient systemic reaction that sometimes follows treatment for syphilis.


Q: Does Bicillin LA require a special diet while it is active in the body?

No special diet is required. The official drug monograph does not document specific interactions with food that necessitate a change in diet while the medicine is active in the body.


Q: What if I miss an injection of Bicillin LA (high-level query)?

General guidance available in official sources advises that receiving all prescribed doses on schedule is necessary for appropriate treatment. Skipping doses or stopping treatment too soon is associated with the risk of incomplete treatment or the potential for bacterial resistance.


Q: What is the consistency of the liquid for Bicillin LA?

The product is officially described as an injectable suspension. Due to the presence of the Benzathine salt component, it is generally known to be a viscous (thick) liquid that is injected slowly into the muscle.


Q: How is Bicillin LA classified in terms of drug safety?

Bicillin L-A is classified as a prescription-only drug and a beta-Lactam antibiotic. Safety profiles include classification by regulatory bodies, such as the TGA (Australia) which places its active ingredient in Pregnancy Category A.


Q: What are the signs that Bicillin LA is working?

Signs that the drug is working are generally evaluated by a healthcare provider. This assessment is based on a review of clinical response (e.g., reduction of symptoms) and, in some cases, follow-up bacteriological studies to confirm the eradication of the organism.


Q: Is Bicillin LA used as a preventative antibiotic in some cases?

Yes. According to official labeling, Bicillin L-A is indicated for the prophylaxis (prevention) of certain conditions. This notably includes the prevention of recurrent rheumatic fever and its subsequent complication, rheumatic heart disease.


Q: Is Bicillin LA the only form of benzathine penicillin G available?

No. Bicillin L-A is one brand name for Benzathine Penicillin G. Official communications, such as drug shortage alerts, have indicated that other forms of Benzathine Penicillin G (like Extencilline or Lentocilin) may be available in the market.


Q: Does Bicillin LA cause nausea or stomach problems?

Yes. Official documentation lists adverse reactions that affect the gastrointestinal system. These include documented side effects such as nausea, vomiting, and diarrhea, and potentially more serious conditions like Clostridioides difficile-associated diarrhea.


Q: How long after an injection can side effects appear?

The appearance of side effects varies. However, one specific event, the Jarisch-Herxheimer reaction, is documented to occur relatively quickly—typically 4 to 6 hours after the injection—and generally resolves within 24 hours.


Q: What are the typical indications for using Bicillin LA in adults?

Official information lists its primary uses, or indications, which include the treatment of certain streptococcal infections (like pharyngitis), various venereal infections (including syphilis, yaws, pinta, and bejel), and the prophylaxis of recurrent rheumatic fever.


Q: How is the potency of Bicillin LA measured?

The potency and dose of Bicillin L-A are measured in units. Regulatory documents list the medicine in standardized amounts such as 600,000 units, 1,200,000 units, and 2,400,000 units.


Q: Why do official documents mention specific injection techniques for Bicillin LA?

Specific administration techniques, such as deep intramuscular (IM) injection, are required because the formulation is a prolonged-release suspension. These techniques are necessary to ensure the correct slow release of the active ingredient from the muscle tissue, achieving the desired long-acting effect.


Q: What is the difference between Bicillin LA and products containing Procaine Penicillin?

The key difference is the composition. Bicillin L-A contains only Benzathine Penicillin G for a solely prolonged effect. Products containing Procaine Penicillin are mixtures of two salts, designed to provide both a rapid onset (from the procaine salt) and prolonged levels.

How should Bicillin LA be stored and disposed of?

The storage and disposal of Bicillin L-A (penicillin G benzathine injectable suspension) must strictly follow official regulatory requirements to maintain product stability.

Required Storage Conditions

Condition Requirement (Official Labeling)
Temperature Store in a refrigerator between 2 C to 8 C (36 F to 46 F).
Prohibited Do not freeze and protect from heat; freezing compromises the suspension.
Protection Keep out of the sight and reach of children.
Container Keep in the original container until administration.

Disposal Instructions

Used syringes and any unused contents must be disposed of safely by a doctor, nurse, or pharmacist according to local pharmaceutical waste guidelines. The used syringe should not be handled or reused. Expired or damaged product should be returned to a pharmacist for disposal and must not be placed into household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bicillin LA found in:

A-Z Index: